Glaukos Corporation

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-05-15 pm EDT			5-day change	1st Jan Change
111.4 ^USD	+0.38%		+4.19%	+40.13%

May. 14	Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing	MT
May. 06	Jefferies Upgrades Glaukos to Buy From Hold, Raises Price Target to $125 From $84	MT

Glaukos Corporation Revises Sales Guidance for the Year 2023

August 02, 2023 at 04:10 pm EDT

Glaukos Corporation revised sales guidance for the year 2023. For the year, the company expects net sales to be in the range of $304 million to $308 million, compared to previous guidance range of $295 million to $300 million.

Latest news about Glaukos Corporation

Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing	May. 14	MT
Jefferies Upgrades Glaukos to Buy From Hold, Raises Price Target to $125 From $84	May. 06	MT
Needham Adjusts Price Target on Glaukos to $113 From $108, Maintains Buy Rating	May. 02	MT
JPMorgan Adjusts Price Target on Glaukos to $110 From $108, Maintains Overweight Rating	May. 02	MT
Truist Raises Glaukos' PT to $125 From $120 After 'Solid' Q1 Beat, Keeps Buy Rating	May. 02	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Revenue $85.6M, vs. Street Est of $79.7M	May. 01	MT
Transcript : Glaukos Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
Glaukos Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	Apr. 11	MT
Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	Apr. 11	MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03	MT
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	Apr. 03	MT
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	Apr. 03	CI
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	Mar. 08	MT
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	Feb. 29	MT
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	Feb. 27	MT
Wells Fargo Hikes Price Target on Glaukos to $103 From $83, Maintains Overweight Rating	Feb. 22	MT
Needham Raises Price Target on Glaukos to $108 From $105, Maintains Buy Rating	Feb. 22	MT
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	Feb. 21	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M	Feb. 21	MT
Transcript : Glaukos Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Glaukos Corporation Reaffirms Financial Guidance for 2024	Feb. 21	CI
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing	Jan. 18	MT
Transcript : Glaukos Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM	Jan. 09

Chart Glaukos Corporation

Duration

Period

More charts

Company Profile

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-30 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Glaukos Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

111.4 USD

Average target price

112.5 USD

Spread / Average Target

+1.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
GLAUKOS CORPORATION	+40.13%	5.61B
STRYKER CORPORATION	+10.86%	126B
SMITH & NEPHEW PLC	-5.70%	11.27B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+4.17%	9.12B
INSPIRE MEDICAL SYSTEMS, INC.	-21.47%	4.75B
AXONICS, INC.	+8.77%	3.45B
ENOVIS CORPORATION	-6.03%	2.89B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-12.05%	2.07B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-7.83%	2.05B
DOUBLE MEDICAL TECHNOLOGY INC.	-22.84%	1.8B

Medical Devices & Implants